TORONTO, Dec. 11, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, today announced that it will be
presenting at the 13th Annual LD Micro Main Event
investor conference on December 14th.
Khiron Chairman Chris Naprawa will
be presenting to a live, virtual audience.
DATE: December 14th,
FORMAT: Live 10 minute presentation & 10 minute Q&A
View the Khiron profile here:
Recent Khiron Developments
- Khiron High THC medical cannabis product successfully imported
into Peru, with first
prescriptions to be filled in December through a partnership with
Farmacia Universal S.A.C.
- Company's medical cannabis products and clinic services are now
covered by Colombia's major health
insurance providers, including medical cannabis as a first line
- Announces the opening of its first Zerenia clinic in
Medellin, Colombia´s second
largest city with reach to over 6 million residents in the
- Mr. Juan Carlos Echeverry is
appointed to the Board of Directors of the Company, bringing
extensive experience as Colombia's
Minister of Finance from 2010-2012 and as CEO and President of
Ecopetrol from 2015-2017
- Completed a bought deal financing on November 26, 2020, for aggregate gross proceeds
of $14,490,000 CAD
- Company surpassed 5,600 patient prescriptions for its medical
cannabis products in Colombia
- The Company plans to deploy its Zerenia™ medical cannabis
clinics and telehealth strategy in Mexico, building on the success of its
vertical integration strategy in Colombia
About LD Micro/SEQUIRE
LD Micro began in 2006 with the
sole purpose of being an independent resource to the microcap
world. What started as a newsletter highlighting unique companies,
has transformed into the pre-eminent event platform in the space.
For more information, please visit ldmicro.com.
The upcoming Main Event will be highlighting a new format that
will benefit both executives and the investors tuning in from all
over the globe.
In September 2020, LD Micro. Inc.
was acquired by SRAX, Inc., a financial technology company that
unlocks data and insights for publicly traded companies. Through
its premier investor intelligence and communications platform,
Sequire, companies can track their investors' behaviors and
trends and use those insights to engage current and potential
investors across marketing channels. For more information on SRAX,
visit srax.com and mysequire.com.
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading cannabis company in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Peru and has a presence in Mexico, Uruguay, UK, Spain and also in Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage and patient-oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with Kuida™
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
SOURCE Khiron Life Sciences Corp.